Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.
about
Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excretedDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingDefining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachPharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Mathematical modeling to characterize the inoculum effect.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B.The treatment of urinary tract infections and use of ciprofloxacin extended release.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designInvestigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelA simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Compensation of fitness costs and reversibility of antibiotic resistance mutations.Pharmacodynamic models of age-structured cell populations.A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.Translational PK/PD of anti-infective therapeutics.Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensive Drug-resistant Pseudomonas aeruginosa.Translational Modeling of Antibacterial Agents
P2860
Q28542920-06C782C3-B9C6-4BAA-AA17-34D3B6422576Q28550711-8B846BF7-730F-4CF5-B6A3-D7EA938BFA1CQ28601378-0AC3227E-C4FC-4BC4-9784-8562E1D858C5Q33555316-52511FAC-FD7D-4D15-A105-C307F39A2EBCQ33601794-D04865F1-2301-433B-B671-AE56A20AC971Q33826267-1B10B436-7BCC-47F2-AD90-4D118E109860Q34290045-10CEBAE0-67DB-4174-8636-B14C75803630Q34737629-A8113736-5285-4746-8A91-73E949480DF7Q35023303-31EF8BA3-4285-452B-B9FB-364BF390D825Q35635652-F0016FF3-63C5-45EA-96C8-DB60521DE0EEQ36162355-BCF1E819-0C5C-4D70-9401-D2ADA0C60144Q36319990-3ED82931-95FE-401E-8E0C-14B02917BC0FQ36458378-B4D27121-C3EA-4182-BE2C-C9AE22414430Q36482785-BFF82AA3-9B9D-4EA0-A553-50CEAE7A8C4AQ36785827-2879B98C-657B-4266-B022-7C2113FEC88CQ37119985-3449100E-4B36-4112-A239-7EED3622283AQ37441394-437BF1D3-AAFF-4D29-AA69-BF10EE17EDFFQ37660762-58F2D6C6-15A9-4E59-BAE3-5E1907D2E934Q37696851-DC5CACFA-B631-4702-A5AF-7E44E46EDE4EQ38588105-415E5D27-EAAD-416B-857F-3BFF550A2F20Q38966188-5DED803C-0BE5-4ED4-8607-4E82700C4706Q39039505-B8E32CFC-89AC-401A-8C50-59204C54206EQ39078187-223965EB-37E1-43C1-AD74-8652E83F6667Q39665401-96917133-AD97-48AF-912D-C89ABA8EA564Q40327149-A119AEF3-817B-47BE-886A-B276A8C7ACEEQ40802708-FF97570D-F905-42D0-8221-54FB042911D1Q42076409-15649CA4-4D2F-4363-9260-51F8AC0259B0Q43215544-F0C72BFD-BDCF-461F-B135-BF11ACB3B86FQ47273930-FCCD6B33-2BD6-4DC8-A5DB-2BC9AB2A26B3Q49667957-DF7D6B4B-889F-451F-8605-3C315E81E397Q49825374-E347C75A-157F-414F-AE3C-23A91BB1329BQ51118472-78E8B935-97A2-4FBB-8784-1F2B8A9E5F1CQ51208291-46F4613C-CD4F-41D9-95EE-60F5493A9201Q52584723-7847604E-9FF2-4AF7-921C-0CAC75E49E2CQ52597958-BB47C016-B224-406A-B79A-7BF1168C5A42Q57240408-930CD2CC-ED35-42BB-9954-94917103AA13
P2860
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Novel pharmacokinetic-pharmaco ...... formulation of ciprofloxacin.
@en
type
label
Novel pharmacokinetic-pharmaco ...... formulation of ciprofloxacin.
@en
prefLabel
Novel pharmacokinetic-pharmaco ...... formulation of ciprofloxacin.
@en
P2093
P2860
P1476
Novel pharmacokinetic-pharmaco ...... formulation of ciprofloxacin.
@en
P2093
Alan Forrest
Alison K Meagher
Axel Dalhoff
Heino Stass
Jerome J Schentag
P2860
P304
P356
10.1128/AAC.48.6.2061-2068.2004
P407
P577
2004-06-01T00:00:00Z